FindTrial
Sign In

Multi-omics reveals the mechanisms of prostate cancer development and progression

Multi-omics reveals the mechanisms of prostate cancer development and progression

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085720
Enrollment
Unknown
Registered
2024-06-17
Start date
2024-07-31
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Fetal group (10 cases)
organ donation group (10 cases)
patients with prostate hyperplasia undergoing transurethral resection group (10 cases)
patients with prostate cancer undergoing radical prostatectomy group (20 cases):None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Miscarriage or stillbirth cases from West China Second University Hospital, Sichuan University. 2. Patients who are brain dead and undergo organ donation in our center. 3. Patients who undergo transurethral resection of the prostate due to prostatic hyperplasia in our center. 4. Patients who undergo radical prostatectomy due to prostate cancer in our center.

Exclusion criteria

Exclusion criteria: 1. Patients with an insufficient sample size. 2. Patients or their family members who do not consent to participate in this study.

Design outcomes

Primary

MeasureTime frame
Transcriptomics;—

Countries

China

Contacts

Public ContactJianzhong Ai; Xiaonan Zheng

Department of Urology, Institute of Urology, West China Hospital, Sichuan University

jianzhong.ai@scu.edu.cn+86 189 0808 0924

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026